CONCLUSION: Our estimation supports the potential cost-effectiveness of multimodal intervention trials, exemplified by J-MINT, for dementia prevention. →

CONCLUSION: Women seem to be more interested in initiatives promoting healthy aging. We have observed differences in dementia risk factors between men and women that could be related to sociocultural gender differences in this range of age. As previous studies have shown, in our study women perform better on brief cognitive tests, making them less… →

CONCLUSION: PlwD had a broad array of unmet healthcare needs, indicating primary healthcare provision improvement potentials. The results underscore the significance of early assessment of patient’s clinical characteristics and unmet needs as a basis for individualized gender-sensible intervention strategies. →

CONCLUSIONS: The IPAT Study had a success with total recruitment yield from the hospital database sources, but less success with virtual resources, referrals, and community outreach activities. However, a multimodal recruitment approach is essential to meet the overall enrollment goal of the project. →

CONCLUSION: Four possible multidomain adherence composite scores are proposed, reflecting intervention engagement in U.S. POINTER. In the future, we will explore sensitivity of each composite score to detect treatment-related change in cognition. This study will lay the foundation for broader applications in other multidomain trials with quantifiable adherence metrics, such as FINGER and LatAm-FINGERS. →

CONCLUSION: Benfotiamine reverses the changes of metabolites/lipids reflecting AD progression. Our ongoing NIH funded multicenter trial includes blood biomarkers of thiamine, amyloid, tau, inflammation, neurodegeneration, AGE, and extensive cognitive testing. A larger sample size is necessary to test whether metabolic biomarkers are useful for disease diagnosis, prognosis, and monitoring therapeutic efficacy. This research was partially… →

CONCLUSION: AXS-05 demonstrated a substantial, rapid reduction in ADA vs controls after 5 weeks of treatment, increased time-to-relapse vs placebo, and was well-tolerated, supporting its development as a promising treatment option for ADA. →

CONCLUSION: Preliminary findings from LatAm-FINGERS highlight the feasibility of conducting intervention trials within diverse populations. These findings underscore the importance of creating recruitment strategies that effectively engage underrepresented groups. This contributes significantly to global Alzheimer’s disease research efforts. The trial’s experience offers a valuable model for inclusive enrollment practices in Alzheimer’s disease and related dementia… →

CONCLUSION: Depending on correlations between prognostic scores and actual trial outcomes, a potential overall sample size reduction of 5-10% could be achieved using DT methodology (PROCOVA^(TM)) while maintaining statistical power, based on Δ CDR-SB and Δ ADAS-Cog 14 in the AWARE study. Sample size savings could enable shortening of the recruitment period and reduce the… →

CONCLUSION: A single bout of tVNS does not appear effective for improving cognition in individuals with MCI. →